Improvement in sequelae of chronic liver disease in patients with Alagille syndrome treated with maralixibat

Abstract Maralixibat (MRX) is an orally administered, small‐molecule ileal bile acid transporter (IBAT) inhibitor used in the treatment of cholestatic pruritus in conditions such as Alagille syndrome (ALGS). MRX's beneficial effects on cholestatic pruritus are well described, however its effects on patients’ clinical manifestations of hepatic disease are less well known. We report two cases of patients with ALGS treated with MRX who demonstrated stabilization of their esophageal varices and xanthomas, respectively. Our findings demonstrate the potential role of MRX in improving the extrahepatic manifestations of liver disease in patients with ALGS. Further studies are needed to understand the physiologic mechanisms driving these changes.

Authors

Institutions

Publication Details

Journal
JPGN Reports
Published
2026-11-12
DOI
https://doi.org/10.1002/jpr3.70262
Primary Topic
Pediatric Hepatobiliary Diseases and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Improvement in sequelae of chronic liver disease in patients with Alagille syndrome treated with maralixibat

Tin Bo Nicholas Lam, Maria Paulina Ordonez, Amber Hidlreth
JPGN Reports
Pediatric Hepatobiliary Diseases and Treatments
article

Improvement in sequelae of chronic liver disease in patients with Alagille syndrome treated with maralixibat

Tin Bo Nicholas Lam, Maria Paulina Ordonez, Amber Hidlreth
article en

Abstract

Abstract Maralixibat (MRX) is an orally administered, small‐molecule ileal bile acid transporter (IBAT) inhibitor used in the treatment of cholestatic pruritus in conditions such as Alagille syndrome (ALGS). MRX's beneficial effects on cholestatic pruritus are well described, however its effects on patients’ clinical manifestations of hepatic disease are less well known. We report two cases of patients with ALGS treated with MRX who demonstrated stabilization of their esophageal varices and xanthomas, respectively. Our findings demonstrate the potential role of MRX in improving the extrahepatic manifestations of liver disease in patients with ALGS. Further studies are needed to understand the physiologic mechanisms driving these changes.

JPGN Reports
University of California San Diego (US)
Pediatric Hepatobiliary Diseases and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon